公司公告2024 年盈利同比下降26%公司发布业绩预告,预计其2024 年全年归母净利润同比下滑约26%;考虑公允价值变动,我们预计经调整净利润降幅低于表观利润下降,符合市场预期。我们测算公司4 季度收入和经调整净利润环比个位数下降。关注要点成药业务收入短期承压。根据公告,公司成药业务2024 年收入下降7%左右,其中1)津优力及多美素两款产品价格在京津冀3+N联盟集中采购中分别下调58%和23%...
Source Link公司公告2024 年盈利同比下降26%公司发布业绩预告,预计其2024 年全年归母净利润同比下滑约26%;考虑公允价值变动,我们预计经调整净利润降幅低于表观利润下降,符合市场预期。我们测算公司4 季度收入和经调整净利润环比个位数下降。关注要点成药业务收入短期承压。根据公告,公司成药业务2024 年收入下降7%左右,其中1)津优力及多美素两款产品价格在京津冀3+N联盟集中采购中分别下调58%和23%...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.